---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-24-000127"
form_type: "8-K"
ticker: "UTMD"
cik: "0000706698"
company_name: "UTAH MEDICAL PRODUCTS INC"
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:23:02.283856+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# UTMD FY2023 EPS up 1% on interest income; revenue down 4%, litigation costs rise

## Summary
- Full year revenue $50.2M (-4% YoY); EPS $4.574 (+1.2%) as lower operating income offset by higher interest income.
- Q4 revenue $12.3M (-9%); net income $4.3M (-6%); gross margin fell to 57.6% from 61.3%.
- Operating income down 15% due to $2.9M biopharma OEM decline and $1.66M litigation costs vs $0.67M in 2022.
- Cash & investments rose to $92.9M; quarterly dividend increased to $0.30/share starting Jan 2024.
- Management expects further GP margin dilution in 2024 as biopharma sales projected to decline significantly.

## SEC filing metadata
- accession: 0001096906-24-000127
- form_type: 8-K
- ticker: UTMD
- cik: 0000706698
- company_name: UTAH MEDICAL PRODUCTS INC
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/706698/000109690624000127/0001096906-24-000127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/706698/000109690624000127/utmd-20240130.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-24-000127
- JSON: https://secwatch.observer/filing/0001096906-24-000127.json
- Plain text: https://secwatch.observer/filing/0001096906-24-000127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.